Azitra, Inc.

AZTR NYSE CIK: 0001701478

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 21 BUSINESS PARK DRIVE, SUITE 6, BRANFORD, CT, 06405
Mailing Address 21 BUSINESS PARK DRIVE, SUITE 6, BRANFORD, CT, 06405
Phone (203) 489-0183
Fiscal Year End 1231
EIN 464478536

Financial Overview

FY2025 FY

$8K
Revenue
-$8.97M
Net Income
$5.70M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 23, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC
8-K Current report of material events March 13, 2026 View on SEC
8-K Current report of material events March 5, 2026 View on SEC
10-K Annual financial report February 27, 2026 View on SEC
8-K Current report of material events February 27, 2026 View on SEC
8-K Current report of material events February 6, 2026 View on SEC
DEF 14A Definitive proxy statement January 2, 2026 View on SEC
4 Insider stock transaction report December 22, 2025 View on SEC
4 Insider stock transaction report December 22, 2025 View on SEC

Annual Reports

10-K February 27, 2026
  • Clinical-stage medical dermatology company leveraging unique microbiome technology for skin disease therapies.
  • Significantly improved cash position to $15.0 million as of December 31, 2025, due to successful capital raising activities.
View Analysis

Material Events

8-K Financial Distress March 13, 2026
High Impact
  • NYSE American accepted Azitra's comprehensive plan to regain compliance.
  • The company is pursuing strategies like capital raising, cost optimization, and strategic partnerships to improve its financial position.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.